Industry Partner News: Update on Roche's RG62026 Phase 2/3 Study

Roche_Logo.svg.png

Roche recently shared an update regarding their phase 2/3 clinical study (study 227) with RG6206, an
investigational anti-myostatin adnectin, in ambulatory boys with Duchenne muscular dystrophy (www.clinicaltrials.gov reference
NCT030393686).

An unexpected technical issue in the drug supply process was detected, potentially impacting the availability of RG6206 for this ongoing study. Their priority is to ensure that boys in the study can continue study drug uninterrupted. To ensure they meet their commitments to new study participants, we have paused recruitment at all sites until we have resolved this situation.

For more information and resources, please see their most recent community update letter.